SCHEMBL20528835

SCHEMBL20528835

N=C(N)c1ccc(OCCCCCCOc2ccc(C(=N)N)cc2Br)c(Br)c1.O=S(=O)(O)CCO.O=S(=O)(O)CCO

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.67
PLAU P00749 1/20 0.67
ST14 Q9Y5Y6 1/20 0.67
POLB P06746 3/20 0.65
ALDH1A1 P00352 2/20 0.65
LMNA P02545 2/20 0.65
RAB9A P51151 2/20 0.65
SMN1; SMN2 Q16637 2/20 0.65
MAPT P10636 2/20 0.65
KDM4E B2RXH2 2/20 0.65
NPC1 O15118 1/20 0.65
ALOX15 P16050 1/20 0.65
BRCA1 P38398 1/20 0.65
HTT P42858 1/20 0.65
GMNN O75496 1/20 0.65
PKM P14618 1/20 0.65
THPO P40225 1/20 0.65
MTOR P42345 1/20 0.65
RECQL P46063 1/20 0.65
BLM P54132 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL985038 1.00 F2 (0.67) F2PLAUST14POLBALDH1A1
SCHEMBL3006160 1.00 F2 (0.67) F2PLAUST14POLBALDH1A1
Dibrompropamidine SCHEMBL30231952 0.96 F2 (0.72) F2PLAUST14POLBALDH1A1
Dibrompropamidine SCHEMBL871570 0.96 F2 (0.72) F2PLAUST14POLBALDH1A1
Dibrompropamidine SCHEMBL2471251 0.96 F2 (0.72) F2PLAUST14POLBALDH1A1
SCHEMBL14599538 0.85 F2 (0.90) F2PLAUST14PRSS1KLK1
SCHEMBL597315 0.85 F2 (0.90) F2PLAUST14PRSS1KLK1
Dibrompropamidine SCHEMBL29709297 0.81 F2 (1.00) F2PLAUST14PRSS1
Dibrompropamidine SCHEMBL292947 0.81 F2 (1.00) F2PLAUST14PRSS1
Dibrompropamidine SCHEMBL29232796 0.81 F2 (0.71) F2PLAUST14PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709829-A1 FILMS AND THEIR USE IN HOME CARE COMPOSITIONS Colgate-Palmolive Company (US) 2026-03-18 EP disclosed
US-12545860-B2 Mannanase variants BASF SE (DE) 2026-02-10 US disclosed
WO-2025007084-A1 FILMS AND THEIR USE IN HOME CARE COMPOSITIONS COLGATE-PALMOLIVE COMPANY (US) 2025-01-02 WO disclosed
EP-4453838-A1 ENVIRONMENTAL ATTRIBUTES FOR CARE COMPOSITION INGREDIENTS BASF SE (DE) 2024-10-30 EP disclosed
CN-118435218-A Environmental attributes of the care composition ingredients 巴斯夫欧洲公司 2024-08-02 CN disclosed
US-20240132808-A1 Storage-Stable Hydrolase Containing Liquids BASF SE (DE) 2024-04-25 US disclosed
CN-117084953-A Hair care or hair cleaning composition or skin care or skin cleaning composition 魏德曼控股股份公司 2023-11-21 CN disclosed
EP-4265237-A1 HAIR CARE OR HAIR CLEANSING OR SKIN CARE OR SKIN CLEANSING COMPOSITION Weidmann Holding AG (CH) 2023-10-25 EP disclosed
CN-116919865-A Dry mixture 魏德曼控股股份公司 2023-10-24 CN disclosed
EP-3606500-B1 PERSONAL CARE COMPOSITION WEIDMANN HOLDING AG (CH) 2023-10-04 EP disclosed
WO-2021105336-A1 COMPOSITIONS COMPRISING POLYMER AND ENZYME BASF SE (DE) 2021-06-03 WO disclosed
WO-2021094127-A1 A FABRIC CARE COMPOSITION COMPRISING HYDROPHOBICALLY MODIFIED POLYALKYLENEIMINE AND A BIOCIDE BASF SE (DE) 2021-05-20 WO disclosed
WO-2021074430-A1 STORAGE-STABLE HYDROLASE CONTAINING LIQUIDS BASF SE (DE) 2021-04-22 WO disclosed
US-20210007941-A1 PERSONAL CARE COMPOSITION WEIDMANN HOLDING AG (CH) 2021-01-14 US disclosed
EP-3687497-A1 TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILM Johnson & Johnson Consumer Inc. (US) 2020-08-05 EP disclosed
CN-111372565-A Topical compositions and methods for treating and preventing bacterial biofilm-associated atopic dermatitis and infections 强生消费者公司 2020-07-03 CN disclosed
EP-3606500-A1 PERSONAL CARE COMPOSITION Weidmann Holding AG (CH) 2020-02-12 EP disclosed
WO-2019064162-A1 TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILM JOHNSON & JOHNSON CONSUMER INC. (US) 2019-04-04 WO disclosed
US-20190091148-A1 TOPICAL COMPOSITION AND METHOD FOR TREATING AND PREVENTING ATOPIC DERMATITIS AND INFECTIONS RELATED TO BACTERIA BIOFILM KENVUE BRANDS LLC 2019-03-28 US disclosed
WO-2018185230-A1 PERSONAL CARE COMPOSITION WEIDMANN HOLDING AG (CH) 2018-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545860-B2 Mannanase variants MAN2A1, MANBA, IDUA F2 3163/4885PLAU 3821/4885ST14 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.